
3 Branded Medicines Company, Cement Maker and Forgings Maker Stocks With a Strong Future Roadmap: Mankind Pharma, JK Lakshmi Cement and Bharat Forge
Mankind Pharma, JK Lakshmi Cement and Bharat Forge: ROE of 10.6% to 11.7% and FY22 to FY26 revenue CAGR of 5.8% to 16.4%. Prices as of 17 Nov 2026.
Updated: 18 Nov 2026 • 3:38 pm
Posted by:

Quick Answer
The three medicine brand, cement and forging stocks to watch are Mankind Pharma, JK Lakshmi Cement and Bharat Forge. Their return on equity ranges from 10.6% to 11.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.8% to 16.4%. Mankind Pharma leads on both return on equity at 11.7% and revenue growth at 16.4% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Medicine brand, cement and forging stocks bring together companies with a visible plan for the years ahead. Mankind Pharma, JK Lakshmi Cement and Bharat Forge cover a branded medicines company, a cement maker and a forgings maker.
This list covers three medicine brand, cement and forging stocks with complete current figures: Mankind Pharma, JK Lakshmi Cement and Bharat Forge. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Medicine Brand, Cement and Forging Stocks?
Medicine brand, cement and forging stocks are listed companies that make and sell branded medicines and consumer health products, make grey and white cement for homes and projects, and make forged and machined parts for vehicles, defence and industry. Their earnings depend on medicine demand, construction activity and vehicle and defence orders.
Medicine Brand, Cement and Forging Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,610 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
| JK Lakshmi Cement | 515.9 | 6,094 | 16.4 | 29.1 | 10.6 | 0.67 |
| Bharat Forge | 1,714.7 | 87,540 | 122.4 | 50.7 | 11.3 | 0.76 |
On valuation, JK Lakshmi Cement trades at a P/E below the industry P/E, while Mankind Pharma and Bharat Forge trade above it, which reflects the growth the market already expects. Readers comparing medicine brand, cement and forging stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in medicine brand, cement and forging stocks can use the coming numbers to test whether growth is holding.
Why Do Medicine Brand, Cement and Forging Stocks Have a Strong Roadmap in India?
Medicine brand, cement and forging stocks have a strong roadmap in India because strong demand for branded medicines, steady home and road building and rising vehicle and defence orders keep widening the market for these companies.
- Branded medicines. Doctors prescribe trusted brands.
- Cement. Homes and roads need steady supply.
- Forgings. Vehicles and defence need strong parts.
Why Mankind Pharma Features Among These Medicine Brand, Cement and Forging Stocks
Among the medicine brand, cement and forging stocks on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%.
Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Why JK Lakshmi Cement Features Among These Medicine Brand, Cement and Forging Stocks
Among the pharma leader, regional cement and auto forgings shares on this list, JK Lakshmi Cement makes grey cement and ready-mix concrete for customers in northern and western India, selling mainly through a strong dealer network under the JK Lakshmi brand.
The company has a return on equity of 10.6%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 6,094 crore. The stock trades at a P/E of 16.4, below the industry P/E of 29.1.
Revenue rose from Rs 5,488 crore in FY22 to Rs 6,875 crore in FY26, a compound annual growth rate of 5.8%. Net profit grew from Rs 276 crore in FY25 to Rs 413 crore in FY26, a rise of 49.5%. In the June 2026 quarter, revenue grew 8.9% year on year to Rs 1,920 crore.
Roadmap: The company is adding cement and clinker capacity in the markets it serves and extending its reach through dealers. Housing and infrastructure projects in its home markets support volume growth.
What to watch: Check capacity expansion progress and volume growth in core regions.
Why Bharat Forge Features Among These Medicine Brand, Cement and Forging Stocks
Among the three companies on this list, Bharat Forge is a Pune-based maker of forgings, axles and chassis components for automotive and industrial customers, and it has a growing defence and aerospace business that includes artillery systems and components.
Revenue rose from Rs 10,657 crore in FY22 to Rs 17,010 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 508 crore in FY23 to Rs 1,089 crore in FY26, which works out to a compound annual growth rate of 28.9%.
In the June 2026 quarter, revenue grew 18.7% year on year to Rs 4,697 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 87,540 crore. The stock trades at a P/E of 122.4, above the industry P/E of 50.7.
Roadmap: The company is widening its mix beyond automotive into defence, aerospace and industrial products, where programmes run for many years. Its forging expertise and global customer base support a range of applications.
What to watch: Check order inflow in defence and aerospace and the share of non-automotive sales.
Mankind Pharma vs JK Lakshmi Cement vs Bharat Forge on Key Financials
The table below sets the three medicine brand, cement and forging stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
| JK Lakshmi Cement | 5,488 | 6,875 | 5.8% | 413 | 6.0% |
| Bharat Forge | 10,657 | 17,010 | 12.4% | 1,089 | 6.4% |
Mankind Pharma posts the highest return on equity in this group at 11.7%. Bharat Forge has the largest FY26 revenue at Rs 17,010 crore, and Mankind Pharma shows the fastest revenue growth with a 16.4% compound annual rate. A useful habit with medicine brand, cement and forging stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
| JK Lakshmi Cement | 1,763 | 1,920 | 8.9% |
| Bharat Forge | 3,958 | 4,697 | 18.7% |
Key Risks to Check Before Investing in Medicine Brand, Cement and Forging Stocks
Every theme carries risks that deserve a check before any decision. For these medicine brand, cement and forging stocks, the main points are: Long-term pharma leader, regional cement and auto forgings shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Input costs. Metal and material prices can move margins.
- Order timing. Defence and space orders can shift between periods.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter medicine brand, cement and forging stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Medicine Brand, Cement and Forging Stocks
Medicine brand, cement and forging stocks suit investors who prefer to study business strength before price moves. Mankind Pharma, JK Lakshmi Cement and Bharat Forge each have a clear plan to grow. Based on the 17 November 2026 close, Mankind Pharma trades at Rs 2,610, JK Lakshmi Cement at Rs 515.9 and Bharat Forge at Rs 1,714.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these medicine brand, cement and forging stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track medicine brand, cement and forging stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are medicine brand, cement and forging stocks?
Ans. Medicine brand, cement and forging stocks are listed companies that make and sell branded medicines and consumer health products, make grey and white cement for homes and projects, and make forged and machined parts for vehicles, defence and industry. Their earnings depend on medicine demand, construction activity and vehicle and defence orders. This list looks at three of them, Mankind Pharma, JK Lakshmi Cement and Bharat Forge, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which medicine brand, cement and forging stocks are covered in this list?
Ans. This list covers Mankind Pharma, JK Lakshmi Cement and Bharat Forge. Based on the 17 November 2026 close, Mankind Pharma traded at Rs 2,610, JK Lakshmi Cement at Rs 515.9 and Bharat Forge at Rs 1,714.7. Their return on equity ranges from 10.6% to 11.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.8% to 16.4%.
Why do medicine brand, cement and forging stocks have a strong future roadmap in India?
Ans. Medicine brand, cement and forging stocks have a strong roadmap in India because strong demand for branded medicines, steady home and road building and rising vehicle and defence orders keep widening the market for these companies. The main drivers are as follows. Branded medicines. Doctors prescribe trusted brands. Cement. Homes and roads need steady supply. Forgings. Vehicles and defence need strong parts. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
How has JK Lakshmi Cement performed financially?
Ans. Revenue rose from Rs 5,488 crore in FY22 to Rs 6,875 crore in FY26, a compound annual growth rate of 5.8%. Net profit grew from Rs 276 crore in FY25 to Rs 413 crore in FY26, a rise of 49.5%. In the June 2026 quarter, revenue grew 8.9% year on year to Rs 1,920 crore. The company has a return on equity of 10.6%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 6,094 crore. The stock trades at a P/E of 16.4, below the industry P/E of 29.1. Looking ahead, the company is adding cement and clinker capacity in the markets it serves and extending its reach through dealers. Housing and infrastructure projects in its home markets support volume growth.
How has Bharat Forge performed financially?
Ans. Revenue rose from Rs 10,657 crore in FY22 to Rs 17,010 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 508 crore in FY23 to Rs 1,089 crore in FY26, which works out to a compound annual growth rate of 28.9%. In the June 2026 quarter, revenue grew 18.7% year on year to Rs 4,697 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 87,540 crore. The stock trades at a P/E of 122.4, above the industry P/E of 50.7. Looking ahead, the company is widening its mix beyond automotive into defence, aerospace and industrial products, where programmes run for many years. Its forging expertise and global customer base support a range of applications.
What risks should investors check before buying medicine brand, cement and forging stocks?
Ans. Investors should check a few risks before buying medicine brand, cement and forging stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Input costs. Metal and material prices can move margins. Order timing. Defence and space orders can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of medicine brand, cement and forging stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





